# To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients

> **NCT00916604** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 24 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** AZD1656
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00916604
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** —
- **Final completion:** 2009-10
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2009-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00916604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00916604, "To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00916604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*